ID   PFSK-1
AC   CVCL_1642
SY   PFSk-1; PFSK1; PFSK
DR   CLO; CLO_0008425
DR   EFO; EFO_0005234
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2060
DR   BioSample; SAMN03471425
DR   cancercelllines; CVCL_1642
DR   Cell_Model_Passport; SIDM01132
DR   ChEMBL-Cells; CHEMBL3308802
DR   ChEMBL-Targets; CHEMBL1075560
DR   Cosmic; 683667
DR   Cosmic; 923655
DR   Cosmic; 973260
DR   Cosmic; 1728490
DR   Cosmic; 1995615
DR   Cosmic-CLP; 683667
DR   DepMap; ACH-001711
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS054ENC
DR   GDSC; 683667
DR   GEO; GSM923430
DR   GEO; GSM1670349
DR   IARC_TP53; 21279
DR   IZSLER; BS TCL 202
DR   LINCS_LDP; LCL-1407
DR   PharmacoDB; PFSK1_1264_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1642
DR   Wikidata; Q54947302
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=1316433;
RX   PubMed=20164919;
RX   PubMed=23325432;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/PFSK-1_protocol.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Population: Caucasian.
CC   Doubling time: ~30 hours (ATCC=CRL-2060).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Gly (c.823T>G); ClinVar=VCV001414106; Zygosity=Homozygous (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.31%; Native American=0%; East Asian, North=2.03%; East Asian, South=0%; South Asian=0.77%; European, North=66.34%; European, South=30.55% (PubMed=30894373).
CC   Derived from site: In situ; Brain, right frontal lobe; UBERON=UBERON_0002810.
ST   Source(s): ATCC; Cosmic-CLP; DepMap
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12,14
ST   D16S539: 13
ST   D18S51: 12
ST   D21S11: 28,32.2
ST   D3S1358: 15,16,18
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 20,22
ST   Penta D: 9,12
ST   Penta E: 12,17
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   1Y10M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994).
//
RX   PubMed=1316433; DOI=10.1097/00005072-199205000-00005;
RA   Fults D.W., Pedone C.A., Morse H.G., Rose J.W., McKay R.D.G.;
RT   "Establishment and characterization of a human primitive
RT   neuroectodermal tumor cell line from the cerebral hemisphere.";
RL   J. Neuropathol. Exp. Neurol. 51:272-280(1992).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//